Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology SocietyAlexander R. Lyon, Daniel J. Lenihan, Teresa López‐Fernández et al.|European Journal of Heart Failure|2020Cited by 767
Organ Dysfunction, Injury and Failure in Acute Heart Failure: From Pathophysiology to Diagnosis and Management. A Review on Behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)Veli‐Pekka Harjola, Alexandre Mebazaa, Wilfried Müllens et al.|European Journal of Heart Failure|2017Cited by 406
Evaluation of Kidney Function Throughout the Heart Failure Trajectory – A Position Statement from the Heart Failure Association of the European Society of CardiologyWilfried Müllens, Andrew J.S. Coats, Kevin Damman et al.|European Journal of Heart Failure|2020Cited by 390
Role of Serum Biomarkers in Cancer Patients Receiving Cardiotoxic Cancer Therapies: A Position Statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of CardiologyRadek Pudil, Alexander R Lyon, Christian Mueller et al.|European Journal of Heart Failure|2020Cited by 344
Treatments targeting inotropyChristoph Maack, Alexandre Mebazaa, Thomas Eschenhagen et al.|European Heart Journal|2018Cited by 227